| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/01/2005 | US20050192248 Adjuvant enhances CD8+ T cell responses; malaria, HIV vaccines; augmenting the immunogenicity of an antigen; use of glycolipids such as 3'S, 4'S, 5'R-3'-hexacosanoyl-4,5'-di-O-acetylnonadecyl-2,3,4,6-tetra-O-acetyl-alpha-C-D-galactopyranoside |
| 09/01/2005 | US20050192247 Method of treating cancers |
| 09/01/2005 | US20050192246 Pharmacologically active agents containing esterified phosphonates and methods for use thereof |
| 09/01/2005 | US20050192245 Medicinal composition for treating arteriosclerosis |
| 09/01/2005 | US20050192244 Histamine release inhibitor |
| 09/01/2005 | US20050192243 Neuromuscular blocking agents and antagonists thereof |
| 09/01/2005 | US20050192242 Therapeutic fusion protein transgenes |
| 09/01/2005 | US20050192238 Modulation of the expression of genes dependent on stat-1 |
| 09/01/2005 | US20050192237 Antisense antibacterial cell division composition and method |
| 09/01/2005 | US20050192236 A substantially crystalline clindamycin free base of three polymorphic/pseudopolymorphic forms; water insoluble so useful for sustained release formulations; storage stability; powder x-ray diffraction; differential scanning calorimetry; bactericides |
| 09/01/2005 | US20050192235 Compositions and methods for treating or preventing diseases of body passageways |
| 09/01/2005 | US20050192234 Crystal forms of azithromycin |
| 09/01/2005 | US20050192233 Composition of matter comprising a lanolin free absorption base and method of making |
| 09/01/2005 | US20050192232 E.g.,N[(R)-3-dodecanoyloxytetradecanoylamino]-C-aspartic acid, alpha-N-{(4R)-5-hydroxy-4-[(R)-3-hydroxytetradecanoyl- amino]pentyl}amide; grafting antigens to modulate immune response and on a pharmaceutical carrier or antibiotic to enhance therapeutic effect or targetting aqueous conjugate injections |
| 09/01/2005 | US20050192229 Treating psoriasis by topically applying to the affected skin areas a high concentration (40-60%) of reduced glutathione; alpha lipoic acid as an adjuvant along with a carrier; antiinflammatory agents; antiallergens; eczema; seborrhea dematitus; roazcea; acne; skin disorders |
| 09/01/2005 | US20050192226 Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants |
| 09/01/2005 | US20050192225 Methods for treating Parkinson's disease |
| 09/01/2005 | US20050192221 Antimicrobial/immune modulatory agent comprising all or part of a polypeptide having an amino acid sequence of SPLUNC1, LPLUNC1, or both, and pharmaceutically acceptable carrier (PLUNC for palate, lung, and nasal epithelium clone); anti-inflammatory agents, respiratory system disorders |
| 09/01/2005 | US20050192218 For producing analgesia in a mammalian subject |
| 09/01/2005 | US20050192213 Echinocandin pharmaceutical formulations containing micelle-forming surfactants |
| 09/01/2005 | US20050192210 Treating or preventing vascular condition in patient by administering locally a therapeutically effective amount of a composition that increases metabolic production of nitric oxide by nitric oxide synthases; treatment of glaucoma, pulmonary hypertension, asthma, chronic obstructive pulmonary disease |
| 09/01/2005 | US20050192208 Cardiovascular disorders; antiarrhythmia agents; sodium channel moderators ; potassium channel moderators; prevent fibrillation |
| 09/01/2005 | US20050192197 Peroxyoctanoic acid, octanoic acid, surfactants, carrier, and solubilizer, oxidizers; can be readily made, and can exhibit reduced odor; microbiocide |
| 09/01/2005 | US20050191747 Recombinant bovine immunodeficiency virus based gene transfer system |
| 09/01/2005 | US20050191711 Cerebral amyloid plaque precursors for use as diagnostic tool in detection of nervous system disorders |
| 09/01/2005 | US20050191696 Compounds, methods of screening, and in vitro and in vivo uses involving anti-apoptotic genes and anti-apoptotic gene products |
| 09/01/2005 | US20050191690 Membrane proteins for identifying modulators for prevention and treatment of infection, cell proliferative, neurological, cardiovascular, gastrointestinal, autoimmune/inflammatory and metabolic disorders |
| 09/01/2005 | US20050191679 Schizochytrium fatty acid synthase (FAS) and products and methods related thereto |
| 09/01/2005 | US20050191653 Oligonucleotide for use in controlling expression of sodium-dependent glucose cotransporters (SGLT2) gene sequenes and treatment of diabetes |
| 09/01/2005 | US20050191649 Identifying mutation in oligoadenylate synthetase gene (OAS1); identifying modulators for prevention and treatment of cell proliferative, nervous system and diabetic disorders |
| 09/01/2005 | US20050191641 Nucleotide sequences coding hydrolase for use as tool in identifying modulators for prevention and treatment of digestion, coagulation, diabetic, cell proliferative, urogenital, eating and nervous system gynecological disorders |
| 09/01/2005 | US20050191621 CD4-independent HIV envelope proteins as vaccines and therapeutics |
| 09/01/2005 | US20050191385 Phyto-derived tetracyclic compounds with steroidal-like activity |
| 09/01/2005 | US20050191375 Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines |
| 09/01/2005 | US20050191373 Agent for the prevention and/or treatment of septicemia |
| 09/01/2005 | US20050191371 Medical composition |
| 09/01/2005 | US20050191370 Combination elicites an antioxidant effect, increase the mean diameter of the strands of hair, decrease the heterogeneity of the diameters of the hairs and increase hair density, thus reflecting regrowth |
| 09/01/2005 | US20050191369 Compositions comprising vitamin E and saw palmetto |
| 09/01/2005 | US20050191368 for administration to male for treating or preventing prostate disease and/or vascular disease, the active components including saw palmetto, vitamin E, selenium, lycopene, zinc, vitamin B12, vitamin B6 and folic acid |
| 09/01/2005 | US20050191367 Administering a therapeutically effective amount of arsenic compounds, optionally along with other non-arsenic therapeutic agents, to a mammal for treating solid tumors |
| 09/01/2005 | US20050191358 Microparticles with adsorbed polynucleotide-containing species |
| 09/01/2005 | US20050191357 Method of manufacturing chemical-containing composite particles |
| 09/01/2005 | US20050191354 Promoting cell regeneration and/or cell differentiation with non-metabolizable sugar and a polymeric absorbent |
| 09/01/2005 | US20050191353 Process for manufacture of stable oral multiple unit pharmaceutical composition containing benzimidazoles |
| 09/01/2005 | US20050191351 A once-daily dosage will give steady state blood levels of trospium of a minimum of about 0.5 ng/ml and a maximum of about 6.0 ng/ml. |
| 09/01/2005 | US20050191350 Tablet prepared by wet granulation of povidone as a binder |
| 09/01/2005 | US20050191349 Sustained release; fast dissolving; for treatment of Alzheimer's disease |
| 09/01/2005 | US20050191348 Neurodegenerative disease, dementia, affective or mood disorder, drug use and dependence, memory loss disorder, acute neurological traumatic disorder or neurotrauma |
| 09/01/2005 | US20050191345 Temperature-sensitive liposomal formulation |
| 09/01/2005 | US20050191342 Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity |
| 09/01/2005 | US20050191341 Encapsulated aqueous solution; stress, tension headaches, attention deficit disorder hyperactivity, claustrophobia, hyperactivity, and anxiety |
| 09/01/2005 | US20050191340 If attempting to dissolve the buprenorphine from the patch, the antagonist also has to be dissolved; abuse is difficult to impossible |
| 09/01/2005 | US20050191338 Gelling agent and a solvent, with a dissolved or suspended drug suitable for transdermal delivery and a skin permeation enhancer |
| 09/01/2005 | US20050191334 Sustained release device for implantation in the vitreal chamber or the posterior segment of the eye releasing a corticosteroid for an extended period of time |
| 09/01/2005 | US20050191333 Therapeutic agents dispersed within modified bioactive binders of a hydrophobic compound bonded to a bioactive binder |
| 09/01/2005 | US20050191332 Method of forming rate limiting barriers for implantable devices |
| 09/01/2005 | US20050191323 Pharmaceutical formulations comprising paclitaxel, derivatives and pharmaceutically acceptable salts thereof |
| 09/01/2005 | US20050191322 Isotonic solutions containing lens epithelial proliferation inhibitors; ophthalmic surgery lens transplanting |
| 09/01/2005 | US20050191309 Induction of antigen specific immunologic tolerance |
| 09/01/2005 | US20050191302 Administering an inducer (sulfasalazine) of hepatic stellate cell apoptosis; selective delivery; fibrosis; inhibiting interaction of a tissue inhibitor of a matrix metalloprotease (TIMP) with a matrix metalloprotease |
| 09/01/2005 | US20050191300 Immunotherapy of autoimmune disorders using antibodies which target B-cells |
| 09/01/2005 | US20050191288 Administering to patient before or simultaneously with surgery at least one heparinase enzyme, wherein heparinase enzyme decreases localized inflammatory response in the tissue of the patient |
| 09/01/2005 | US20050191283 Methods of treating NFAT-related disorders |
| 09/01/2005 | US20050191277 Methods of treating various cancers using melanoma differentiation associated protein-7 |
| 09/01/2005 | US20050191276 Treatment of inflammatory bowel disease through induction of indoleamine 2.3-dioxygenase |
| 09/01/2005 | US20050191270 Anti-infectious hydrogel compositions |
| 09/01/2005 | US20050191266 Prophylaxis or treatment of inflammatory skin conditions |
| 09/01/2005 | US20050191260 Hair growth formulation |
| 09/01/2005 | US20050191248 such as silk or bleomycin; treatment for a dental condition such as periodontal disease |
| 09/01/2005 | US20050191247 Alcohol free chlorhexidine diacetate or chlorhexidine dihydrochloride; antibacteria; flavoring agent |
| 09/01/2005 | US20050191244 Abuse-resistant pharmaceutical dosage form |
| 09/01/2005 | US20050191241 Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor |
| 09/01/2005 | DE19964224B4 Pharmazeutische Mittel enthaltend Calcium-Komplex von Pharmaceutical preparations containing calcium complex of [[(4R)-4-[bis[(carboxy-.kappa.O)methyl]amino-.kappa.N]-6,9-bis[(carboxy-.kappa.O)methyl]-1-[(4,4-diphenylcyclohexyl)oxy]-1-hydroxy-2-oxa-6,9-diaza-1-phosphaundecan-11-yl-säure-.kappa.N6,.kappa.N9,.kappa.011]1-oxidato(6-)]-, tetrahydrogen (MS-325) und dessen Salze sowie Verfahren zur Herstellung der Mittel tetra hydrogen (MS-325) and salts thereof as well as methods for preparing the compositions |
| 09/01/2005 | DE102004061271A1 Local application of taurolidine, useful for treatment of tumors and inflammation, by applying as a mixture with a fibrin glue to the tumor cavity |
| 09/01/2005 | DE102004050703A1 New calcium lactate malate useful as a food additive or for producing pharmaceutical compositions, especially for treating osteoporosis |
| 09/01/2005 | DE102004009152A1 Using ascorbic acid and its derivatives for treating teleangiektasia and vascular slackness, and for tightening superficial blood vessels |
| 09/01/2005 | DE102004008112A1 New 8-aminopiperidinyl-xanthine derivatives, useful for treating e.g. diabetes, arthritis and osteoporosis, are inhibitors of dipeptidylpeptidase-IV |
| 09/01/2005 | DE102004007854A1 Stabile, wässrige Formulierung für Benzimidazole Stable, aqueous formulation for benzimidazoles |
| 09/01/2005 | DE102004005788A1 Zubereitungen enthaltend Echinacea-Auszüge und Thiocyanat Preparations containing Echinacea extracts and thiocyanate |
| 09/01/2005 | DE102004005009A1 Verzögert freisetzende pharmazeutische Zusammensetzung von Indapamid The sustained release pharmaceutical composition of indapamide |
| 09/01/2005 | DE102004004906A1 New oxygen-bridged angucyclinone derivatives, useful for treating bacterial infections and dementia, are modulators of intracellular calcium levels |
| 09/01/2005 | DE102004003030A1 Composition containing a dihydroanthracene-disulfonic acid derivative, useful for treating inflammation of internal organs, e.g. ulcers, and cancer |
| 09/01/2005 | DE102004001871A1 Tricyclische Benzazepin-Derivate und ihre Verwendung Tricyclic benzazepine derivatives and their use |
| 09/01/2005 | CA2816904A1 Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof |
| 09/01/2005 | CA2560446A1 Alkyl carbamate-substituted butyrolactones serving as lipase inhibitors |
| 09/01/2005 | CA2559398A1 Pyrrole-3-carboxamide derivatives for the treatment of obesity |
| 09/01/2005 | CA2558770A1 Use of tweak modulators and inhibitors for the treatment of neurological conditions |
| 09/01/2005 | CA2557837A1 Fructoseamine 3 kinase and the formation of collagen and elastin |
| 09/01/2005 | CA2557595A1 Vectors having both isoforms of beta-hexosaminidase and uses of the same |
| 09/01/2005 | CA2557540A1 A cancer combination therapy comprising an antitumor agent and an hdac inhibitor |
| 09/01/2005 | CA2557539A1 Indanol derivative |
| 09/01/2005 | CA2557524A1 Biocompatible polymeric delivery systems for sustained release of quinazolinones |
| 09/01/2005 | CA2557433A1 Quinazoline derivatives and therapeutic use thereof |
| 09/01/2005 | CA2557424A1 Methods for protein production |
| 09/01/2005 | CA2557392A1 Preventive or therapeutic agents for severe diabetic retinopathy |
| 09/01/2005 | CA2557256A1 Pharmacologically acceptable salts of clopidogrel |
| 09/01/2005 | CA2557158A1 Prophylactic antimigraine agents |
| 09/01/2005 | CA2557116A1 Method for treatment or prevention of osteoporosis in individuals with high bone turnover |
| 09/01/2005 | CA2556940A1 Modulator |
| 09/01/2005 | CA2556870A1 Dopamine-agonist combination therapy for improving sleep quality |